STOCK TITAN

OnKure Therapeutics: BVF reports 9.99% deemed stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. (OKUR) is the issuer in an amended beneficial-ownership report from Biotechnology Value Fund, L.P.; BVF I GP LLC; Biotechnology Value Fund II, L.P.; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF GP Holdings LLC; BVF Partners L.P.; BVF Inc.; and Mark N. Lampert, a director and officer of BVF Inc. As of September 30, 2026, the three funds reported beneficial ownership of 2,089,828 shares (5.2%), 1,588,168 shares (3.9%) and 278,594 shares (0.7%), respectively.

BVF Partners L.P., BVF Inc. and Lampert each may be deemed to beneficially own 4,045,278 shares (9.99%), including shares attributed through the funds and a managed account; these attributions overlap and are not separate share blocks. The reporting persons and managed account held pre-funded warrants for 2,147,534 shares, exercisable at $0.0001 per share, but a 4.9% ownership blocker prohibited exercise of any of them as of September 30, 2026. OnKure had 40,496,309 shares outstanding as of August 3, 2026, the basis stated for the ownership percentages.

BVF beneficial ownership 2,089,828 shares (5.2%) As of September 30, 2026
Biotechnology Value Fund II beneficial ownership 1,588,168 shares (3.9%) As of September 30, 2026
Trading Fund OS beneficial ownership 278,594 shares (0.7%) As of September 30, 2026
Deemed beneficial ownership attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert 4,045,278 shares (9.99%) each As of September 30, 2026; overlapping attributions
Shares underlying pre-funded warrants 2,147,534 shares Warrants held by reporting persons and Partners Managed Account
Pre-funded warrant exercise price $0.0001 per share Warrants exercisable immediately, subject to the 4.9% blocker
Pre-Funded Warrants Blocker 4.9% As of September 30, 2026, prohibited exercise of the covered warrants
Shares outstanding 40,496,309 shares As of August 3, 2026; basis for ownership percentages
Pre-Funded Warrants financial
"held pre-funded warrants (the “Pre-Funded Warrants”) exercisable"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Pre-Funded Warrants Blocker technical
"the “Pre-Funded Warrants Blocker”"
Rule 13d-3 regulatory
"for purposes of Rule 13d-3 under the Exchange Act"
Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.
Section 13(d) group regulatory
"persons who are members of a Section 13(d) group"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many OKUR shares did the reporting funds beneficially own?

As of September 30, 2026, Biotechnology Value Fund, L.P. reported 2,089,828 shares (5.2%); Biotechnology Value Fund II, L.P. reported 1,588,168 shares (3.9%); and Biotechnology Value Trading Fund OS LP reported 278,594 shares (0.7%).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





68277Q105

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading